Literature DB >> 33662472

Advanced nanomedicine and cancer: Challenges and opportunities in clinical translation.

Juan Gonzalez-Valdivieso1, Alessandra Girotti2, Jose Schneider3, Francisco Javier Arias4.   

Abstract

Cancer has reached pandemic dimensions in the whole world. Although current medicine offers multiple treatment options against cancer, novel therapeutic strategies are needed due to the low specificity of chemotherapeutic drugs, undesired side effects and the presence of different incurable types of cancer. Among these new strategies, nanomedicine arises as an encouraging approach towards personalized medicine with high potential for present and future cancer patients. Therefore, nanomedicine aims to develop novel tools with wide potential in cancer treatment, imaging or even theranostic purposes. Even though numerous preclinical studies have been published with successful preliminary results, promising nanosystems have to face multiple obstacles before adoption in clinical practice as safe options for patients with cancer. In this MiniReview, we provide a short overview on the latest advances in current nanomedicine approaches, challenges and promising strategies towards more accurate cancer treatment.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Chemotherapy; Drug delivery; Nanodrugs; Nanomedicine

Year:  2021        PMID: 33662472     DOI: 10.1016/j.ijpharm.2021.120438

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  10 in total

Review 1.  Craft of Co-encapsulation in Nanomedicine: A Struggle To Achieve Synergy through Reciprocity.

Authors:  Sourav Bhattacharjee
Journal:  ACS Pharmacol Transl Sci       Date:  2022-05-02

2.  Assembling p53 Activating Peptide With CeO2 Nanoparticle to Construct a Metallo-Organic Supermolecule Toward the Synergistic Ferroptosis of Tumor.

Authors:  Jingmei Wang; Wenguang Yang; Xinyuan He; Zhang Zhang; Xiaoqiang Zheng
Journal:  Front Bioeng Biotechnol       Date:  2022-06-28

3.  The long-circulating effect of pegylated nanoparticles revisited via simultaneous monitoring of both the drug payloads and nanocarriers.

Authors:  Wufa Fan; Haixia Peng; Zhou Yu; Luting Wang; Haisheng He; Yuhua Ma; Jianping Qi; Yi Lu; Wei Wu
Journal:  Acta Pharm Sin B       Date:  2021-11-18       Impact factor: 14.903

Review 4.  What Zebrafish and Nanotechnology Can Offer for Cancer Treatments in the Age of Personalized Medicine.

Authors:  María Cascallar; Sandra Alijas; Alba Pensado-López; Abi Judit Vázquez-Ríos; Laura Sánchez; Roberto Piñeiro; María de la Fuente
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

Review 5.  Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles.

Authors:  Alberto Juan; María Del Mar Noblejas-López; María Arenas-Moreira; Carlos Alonso-Moreno; Alberto Ocaña
Journal:  Front Cell Dev Biol       Date:  2022-02-03

Review 6.  Recent Progress of Novel Nanotechnology Challenging the Multidrug Resistance of Cancer.

Authors:  Chengyuan Zhang; Xuemei Zhou; Hanyi Zhang; Xuanliang Han; Baijun Li; Ran Yang; Xing Zhou
Journal:  Front Pharmacol       Date:  2022-02-14       Impact factor: 5.810

Review 7.  Current and Future Advancements of Raman Spectroscopy Techniques in Cancer Nanomedicine.

Authors:  Elisabetta Canetta
Journal:  Int J Mol Sci       Date:  2021-12-05       Impact factor: 5.923

Review 8.  Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview.

Authors:  Abdullah K Alshememry; Nasser B Alsaleh; Nora Alkhudair; Rami Alzhrani; Aws Alshamsan
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

9.  Myelosuppression Alleviation and Hematopoietic Regeneration by Tetrahedral-Framework Nucleic-Acid Nanostructures Functionalized with Osteogenic Growth Peptide.

Authors:  Tianxu Zhang; Mi Zhou; Dexuan Xiao; Zhiqiang Liu; Yueying Jiang; Maogeng Feng; Yunfeng Lin; Xiaoxiao Cai
Journal:  Adv Sci (Weinh)       Date:  2022-07-26       Impact factor: 17.521

10.  Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses.

Authors:  Jeongrae Kim; Yongwhan Choi; Suah Yang; Jaewan Lee; Jiwoong Choi; Yujeong Moon; Jinseong Kim; Nayeon Shim; Hanhee Cho; Man Kyu Shim; Sangmin Jeon; Dong-Kwon Lim; Hong Yeol Yoon; Kwangmeyung Kim
Journal:  Pharmaceutics       Date:  2022-02-22       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.